TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Inpatient Volume Expansion in Children With Shiga Toxin-Producing Escherichia Coli (STEC) Infection to Prevent Hemolytic Uremic Syndrome (HUS)
Brief Summary: This study will provide feasibility data regarding the conduct of a clinical trail evaluating the use of early aggressive inpatient intravenous rehydration in children with Shiga Toxin producing E. coli infection.


Options:
A: Arm Label: SYNSORB Pk; Type: EXPERIMENTAL; Interventions: Drug: SYNSORB Pk | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: SYNSORB Pk; Assigned to Arm(s): SYNSORB Pk | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Eculizumab; Type: EXPERIMENTAL; Interventions: Drug: Eculizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Eculizumab; Assigned to Arm(s): Eculizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Stage 1 - high treatment arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: INM004 | Arm Label: Stage 1 - Low treatment arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: INM004 | Arm Label: Stage 1 - Placebo arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Stage 2 - Selected active treatment arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: INM004 | Arm Label: Stage 2 - Placebo arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: INM004; Assigned to Arm(s): Stage 1 - Low treatment arm, Stage 1 - high treatment arm, Stage 2 - Selected active treatment arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Stage 1 - Placebo arm, Stage 2 - Placebo arm
D: Arm Label: Admission/Intravascular Volume Expansion; Type: EXPERIMENTAL; Interventions: Drug: D5-0.9%NS | Arm Label: Outpatient Observation; Type: ACTIVE_COMPARATOR; Interventions: Drug: Routine home oral rehydration | Intervention Type: DRUG; Name: D5-0.9%NS; Assigned to Arm(s): Admission/Intravascular Volume Expansion | Intervention Type: DRUG; Name: Routine home oral rehydration; Assigned to Arm(s): Outpatient Observation

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: International Phase III Randomised Study to Evaluate the Efficacy of Maintenance Therapy With Olaparib and Cediranib or Olaparib Alone in Patients With Relapsed Ovarian Cancer Following a Response to Platinum-based Chemotherapy
Brief Summary: ICON 9 will assess the efficacy, safety and tolerability of maintenance olaparib in combination with cediranib compared to maintenance olaparib alone following a response to platinum-based chemotherapy in women with relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer. Prognostic and predictive factors will be studied from tumour and blood samples.


Options:
A: Arm Label: Olaparib and Cediranib; Type: EXPERIMENTAL; Interventions: Drug: Olaparib, Drug: Cediranib | Arm Label: Olaparib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olaparib | Intervention Type: DRUG; Name: Olaparib; Assigned to Arm(s): Olaparib, Olaparib and Cediranib | Intervention Type: DRUG; Name: Cediranib; Assigned to Arm(s): Olaparib and Cediranib
B: Arm Label: Farletuzumab; Type: EXPERIMENTAL; Interventions: Drug: Farletuzumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Farletuzumab; Assigned to Arm(s): Farletuzumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Aflibercept 2.0 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) | Arm Label: Aflibercept 4.0 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) | Intervention Type: DRUG; Name: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®); Assigned to Arm(s): Aflibercept 4.0 mg/kg | Intervention Type: DRUG; Name: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®); Assigned to Arm(s): Aflibercept 2.0 mg/kg
D: Arm Label: 1 non-continuous; Type: OTHER; Interventions: Drug: Sunitinib | Arm Label: 2 continuous; Type: OTHER; Interventions: Drug: SUNITINIB | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): 1 non-continuous | Intervention Type: DRUG; Name: SUNITINIB; Assigned to Arm(s): 2 continuous

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: International Phase III Randomised Study to Evaluate the Efficacy of Maintenance Therapy With Olaparib and Cediranib or Olaparib Alone in Patients With Relapsed Ovarian Cancer Following a Response to Platinum-based Chemotherapy
Brief Summary: ICON 9 will assess the efficacy, safety and tolerability of maintenance olaparib in combination with cediranib compared to maintenance olaparib alone following a response to platinum-based chemotherapy in women with relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer. Prognostic and predictive factors will be studied from tumour and blood samples.


Options:
A: Arm Label: PLD 40 mg/m2 plus VTX-2337; Type: EXPERIMENTAL; Interventions: Drug: pegylated liposomal doxorubicin (PLD), Drug: VTX-2337 | Arm Label: PLD 40 mg/m2 plus placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: pegylated liposomal doxorubicin (PLD), Drug: Placebo | Intervention Type: DRUG; Name: pegylated liposomal doxorubicin (PLD); Assigned to Arm(s): PLD 40 mg/m2 plus VTX-2337, PLD 40 mg/m2 plus placebo | Intervention Type: DRUG; Name: VTX-2337; Assigned to Arm(s): PLD 40 mg/m2 plus VTX-2337 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): PLD 40 mg/m2 plus placebo
B: Arm Label: Olaparib and Cediranib; Type: EXPERIMENTAL; Interventions: Drug: Olaparib, Drug: Cediranib | Arm Label: Olaparib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olaparib | Intervention Type: DRUG; Name: Olaparib; Assigned to Arm(s): Olaparib, Olaparib and Cediranib | Intervention Type: DRUG; Name: Cediranib; Assigned to Arm(s): Olaparib and Cediranib
C: Arm Label: chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel, Drug: Carboplatin, Drug: pegylated liposomal doxorubicin, Drug: Gemcitabine | Arm Label: Chemotherapy and bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Paclitaxel, Drug: Carboplatin, Drug: pegylated liposomal doxorubicin, Drug: Gemcitabine | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Chemotherapy and bevacizumab | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Chemotherapy and bevacizumab, chemotherapy | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Chemotherapy and bevacizumab, chemotherapy | Intervention Type: DRUG; Name: pegylated liposomal doxorubicin; Assigned to Arm(s): Chemotherapy and bevacizumab, chemotherapy | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Chemotherapy and bevacizumab, chemotherapy
D: Arm Label: AMG 386; Type: EXPERIMENTAL; Interventions: Drug: AMG 386, Drug: Paclitaxel | Arm Label: AMG 386 Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: AMG 386 Placebo, Drug: Paclitaxel | Intervention Type: DRUG; Name: AMG 386; Assigned to Arm(s): AMG 386 | Intervention Type: DRUG; Name: AMG 386 Placebo; Assigned to Arm(s): AMG 386 Placebo | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): AMG 386 | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): AMG 386 Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Investigation for Individualized Noninvasive Neuromodulation in Neurorehabilitation of Brain Disease: Longitudinal Study
Brief Summary: Repetitive transcranial magnetic stimulation (rTMS) or transcranial direct current stimulation (tDCS) has been used for the modulation of stroke patients' motor function by altering the cortical excitability. Recently, more challenging approaches, such as stimulation of two or more sites or use of dual modality have been studied in stroke patients. In this study, simultaneous stimulation using both rTMS and tDCS (dual-mode stimulation) over bilateral primary motor cortices (M1s) was investigated to compare its modulatory effects with single rTMS stimulation in subacute stroke patients.


Options:
A: Arm Label: Dual-mode stimulation; Type: EXPERIMENTAL; Interventions: Device: rTMS on ipsilesional M1, Device: tDCS on contralesional M1 | Arm Label: Single stimulation; Type: EXPERIMENTAL; Interventions: Device: rTMS on ipsilesional M1 | Intervention Type: DEVICE; Name: rTMS on ipsilesional M1; Assigned to Arm(s): Dual-mode stimulation, Single stimulation | Intervention Type: DEVICE; Name: tDCS on contralesional M1; Assigned to Arm(s): Dual-mode stimulation
B: Arm Label: cTBS; Type: ACTIVE_COMPARATOR; Interventions: Device: cTBS | Arm Label: cathodal tDCS; Type: ACTIVE_COMPARATOR; Interventions: Device: cathodal tDCS | Arm Label: sham stimulation; Type: SHAM_COMPARATOR; Interventions: Device: sham stimulation | Intervention Type: DEVICE; Name: cTBS; Assigned to Arm(s): cTBS | Intervention Type: DEVICE; Name: cathodal tDCS; Assigned to Arm(s): cathodal tDCS | Intervention Type: DEVICE; Name: sham stimulation; Assigned to Arm(s): sham stimulation
C: Arm Label: tDCS plus wrist robot therapy; Type: EXPERIMENTAL; Interventions: Device: tDCS plus wrist robot therapy | Arm Label: Sham tDCS plus wrist robot therapy; Type: SHAM_COMPARATOR; Interventions: Device: Sham tDCS plus wrist robot therapy | Intervention Type: DEVICE; Name: tDCS plus wrist robot therapy; Assigned to Arm(s): tDCS plus wrist robot therapy | Intervention Type: DEVICE; Name: Sham tDCS plus wrist robot therapy; Assigned to Arm(s): Sham tDCS plus wrist robot therapy
D: Arm Label: real-tDCS with MI-BCI; Type: ACTIVE_COMPARATOR; Interventions: Device: real-tDCS with MI-BCI | Arm Label: sham-tDCS with MI-BCI; Type: SHAM_COMPARATOR; Interventions: Device: real-tDCS with MI-BCI | Intervention Type: DEVICE; Name: real-tDCS with MI-BCI; Assigned to Arm(s): real-tDCS with MI-BCI, sham-tDCS with MI-BCI

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Hope Soap Study: a Randomized Controlled Trial of a Hand-washing Intervention Among Children in South Africa
Brief Summary: The Hope Soap Study is a randomised-control pilot study of a hand-washing intervention in which children in treatment households received a bi-monthly delivery of HOPE SOAP©, a colourful, translucent bar of soap with a toy embedded in its centre.


Options:
A: Arm Label: Community behaviour change campaign; Type: EXPERIMENTAL; Interventions: Behavioral: Community behaviour change campaign | Arm Label: No community behaviour change campaign; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Community behaviour change campaign; Assigned to Arm(s): Community behaviour change campaign
B: Arm Label: Handwashing; Type: EXPERIMENTAL; Interventions: Other: handwashing | Arm Label: handwashing and water treatment; Type: EXPERIMENTAL; Interventions: Other: handwashing, Other: flocculent-disinfectant for water treatment | Arm Label: Water treatment with sodium hypochlorite; Type: EXPERIMENTAL; Interventions: Other: water treatment with sodium hypochlorite | Arm Label: Water treatment with flocculent-disinfectant; Type: EXPERIMENTAL; Interventions: Other: flocculent-disinfectant for water treatment | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: handwashing; Assigned to Arm(s): Handwashing, handwashing and water treatment | Intervention Type: OTHER; Name: flocculent-disinfectant for water treatment; Assigned to Arm(s): Water treatment with flocculent-disinfectant, handwashing and water treatment | Intervention Type: OTHER; Name: water treatment with sodium hypochlorite; Assigned to Arm(s): Water treatment with sodium hypochlorite
C: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Handwashing Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Scaling Up Handwashing Behavior Change | Arm Label: Sanitation Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Total Sanitation and Sanitation Marketing | Arm Label: Combined; Type: EXPERIMENTAL; Interventions: Behavioral: Total Sanitation and Sanitation Marketing, Behavioral: Scaling Up Handwashing Behavior Change | Intervention Type: BEHAVIORAL; Name: Total Sanitation and Sanitation Marketing; Assigned to Arm(s): Combined, Sanitation Intervention | Intervention Type: BEHAVIORAL; Name: Scaling Up Handwashing Behavior Change; Assigned to Arm(s): Combined, Handwashing Intervention
D: Arm Label: Hope Soap group; Type: EXPERIMENTAL; Interventions: Combination Product: Hope Soap | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Combination Product: Control group soap | Intervention Type: COMBINATION_PRODUCT; Name: Hope Soap; Assigned to Arm(s): Hope Soap group | Intervention Type: COMBINATION_PRODUCT; Name: Control group soap; Assigned to Arm(s): Control group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A PHASE 3B/4, MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL GROUP STUDY OF TOFACITINIB (CP-690,550) IN SUBJECTS WITH ULCERATIVE COLITIS IN STABLE REMISSION
Brief Summary: This study is a follow up study for subjects with Ulcerative Colitis (UC) in stable remission designed to evaluate flexible dosing of CP-690,550.


Options:
A: Arm Label: tofacitinib 10 mg BID; Type: EXPERIMENTAL; Interventions: Drug: tofacitinib | Arm Label: Placebo BID; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: tofacitinib; Assigned to Arm(s): tofacitinib 10 mg BID | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo BID
B: Arm Label: 15 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP- 690 550 | Arm Label: 10 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP- 690 550 | Arm Label: 3 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP- 690 550 | Arm Label: 0.5 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP- 690 550 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: CP- 690 550; Assigned to Arm(s): 15 mg BID | Intervention Type: DRUG; Name: CP- 690 550; Assigned to Arm(s): 10 mg BID | Intervention Type: DRUG; Name: CP- 690 550; Assigned to Arm(s): 3 mg BID | Intervention Type: DRUG; Name: CP- 690 550; Assigned to Arm(s): 0.5 mg BID | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Placebo
C: Arm Label: Active 5mg; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Active 10 mg; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Placebo Sequence 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Placebo Sequence 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active 5mg | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active 10 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Sequence 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Sequence 2
D: Arm Label: CP-690,550 5 mg; Type: EXPERIMENTAL; Interventions: Drug: CP-690,500 5 mg | Arm Label: CP-690,550 10 mg; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 10 mg | Intervention Type: DRUG; Name: CP-690,500 5 mg; Assigned to Arm(s): CP-690,550 5 mg | Intervention Type: DRUG; Name: CP-690,550 10 mg; Assigned to Arm(s): CP-690,550 10 mg

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof of Concept Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects With Bladder Pain Syndrome/Interstitial Cystitis
Brief Summary: The purpose of this study is to investigate efficacy, safety and tolerability of ASP6294 in female participants with Bladder Pain Syndrome/Interstitial Cystitis (BPS/IC). This study will also investigate the pharmacokinetics (PK) and pharmacodynamics (PD) of ASP6294 in female participants with BPS/IC.


Options:
A: Arm Label: Pentosan polysulfate sodium 100 mg once a day; Type: EXPERIMENTAL; Interventions: Drug: Pentosan polysulfate sodium 100 mg | Arm Label: Pentosan polysulfate sodium 100 mg three times a day; Type: EXPERIMENTAL; Interventions: Drug: Pentosan polysulfate sodium 100 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pentosan polysulfate sodium 100 mg; Assigned to Arm(s): Pentosan polysulfate sodium 100 mg three times a day | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Pentosan polysulfate sodium 100 mg; Assigned to Arm(s): Pentosan polysulfate sodium 100 mg once a day
B: Arm Label: AQX-1125; Type: EXPERIMENTAL; Interventions: Drug: AQX-1125 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: AQX-1125; Assigned to Arm(s): AQX-1125 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Biological: Tanezumab | Arm Label: Group 2; Type: EXPERIMENTAL; Interventions: Biological: Tanezumab | Arm Label: Group 3; Type: EXPERIMENTAL; Interventions: Biological: Tanezumab | Arm Label: Group 4; Type: EXPERIMENTAL; Interventions: Biological: Tanezumab | Arm Label: Group 5; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: BIOLOGICAL; Name: Tanezumab; Assigned to Arm(s): Group 1 | Intervention Type: BIOLOGICAL; Name: Tanezumab; Assigned to Arm(s): Group 2 | Intervention Type: BIOLOGICAL; Name: Tanezumab; Assigned to Arm(s): Group 3 | Intervention Type: BIOLOGICAL; Name: Tanezumab; Assigned to Arm(s): Group 4 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Group 5
D: Arm Label: ASP6294; Type: EXPERIMENTAL; Interventions: Drug: ASP6294 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: ASP6294; Assigned to Arm(s): ASP6294 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Salad Bars and Students' Fruit and Vegetable Consumption: A Group-randomized Trial With Objective Assessments
Brief Summary: The investigators propose an efficacy study (i.e., do salad bars work under controlled conditions in naturalistic settings) to test whether introducing salad bars in elementary, middle, and high schools that have never had salad bars affects students' FV consumption and waste during lunch. A cluster randomized controlled trial will test new salad bars against controls for 6 wks, with/without an additional 4-wk marketing phase .


Options:
A: Arm Label: Experimental 3; Type: EXPERIMENTAL; Interventions: Behavioral: New salad bar, Behavioral: Marketing | Arm Label: Experimental 2; Type: EXPERIMENTAL; Interventions: Behavioral: Marketing | Arm Label: Experimental 1; Type: EXPERIMENTAL; Interventions: Behavioral: New salad bar | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: New salad bar; Assigned to Arm(s): Experimental 1, Experimental 3 | Intervention Type: BEHAVIORAL; Name: Marketing; Assigned to Arm(s): Experimental 2, Experimental 3
B: Arm Label: intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention | Arm Label: Wait-listed control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Intervention; Assigned to Arm(s): intervention
C: Arm Label: Mobile phone based intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Mobile phone based intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Mobile phone based intervention; Assigned to Arm(s): Mobile phone based intervention
D: Arm Label: Intervention arm; Type: EXPERIMENTAL; Interventions: Behavioral: Healthy Start | Arm Label: Control arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Healthy Start; Assigned to Arm(s): Intervention arm

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Salad Bars and Students' Fruit and Vegetable Consumption: A Group-randomized Trial With Objective Assessments
Brief Summary: The investigators propose an efficacy study (i.e., do salad bars work under controlled conditions in naturalistic settings) to test whether introducing salad bars in elementary, middle, and high schools that have never had salad bars affects students' FV consumption and waste during lunch. A cluster randomized controlled trial will test new salad bars against controls for 6 wks, with/without an additional 4-wk marketing phase .


Options:
A: Arm Label: Treatment; Type: EXPERIMENTAL; Interventions: Other: Childhood Obesity | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Childhood Obesity; Assigned to Arm(s): Treatment
B: Arm Label: CHAMP group; Type: EXPERIMENTAL; Interventions: Behavioral: CHAMP | Arm Label: CHAMP+ group; Type: EXPERIMENTAL; Interventions: Behavioral: CHAMP, Behavioral: CHAMP+ | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: CHAMP; Assigned to Arm(s): CHAMP group, CHAMP+ group | Intervention Type: BEHAVIORAL; Name: CHAMP+; Assigned to Arm(s): CHAMP+ group
C: Arm Label: Immediate Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Healthy Eating and Physical Activity | Arm Label: Delayed Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Healthy Eating and Physical Activity | Intervention Type: BEHAVIORAL; Name: Healthy Eating and Physical Activity; Assigned to Arm(s): Delayed Intervention, Immediate Intervention
D: Arm Label: Experimental 3; Type: EXPERIMENTAL; Interventions: Behavioral: New salad bar, Behavioral: Marketing | Arm Label: Experimental 2; Type: EXPERIMENTAL; Interventions: Behavioral: Marketing | Arm Label: Experimental 1; Type: EXPERIMENTAL; Interventions: Behavioral: New salad bar | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: New salad bar; Assigned to Arm(s): Experimental 1, Experimental 3 | Intervention Type: BEHAVIORAL; Name: Marketing; Assigned to Arm(s): Experimental 2, Experimental 3

Answer: D